Target intelligence / Profile preview

Tissue inhibitor of metalloproteinases-1 (TIMP-1)

Target
TIMP-1
Molecular classification
Enzyme inhibitor, Protease inhibitor, Cytokine, Growth factor
01

Overview

Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a secreted 28-kDa glycoprotein that plays a pivotal role in regulating the extracellular matrix (ECM) by acting as a natural, stoichiometric inhibitor of most active matrix metalloproteinases (MMPs). By forming tight 1:1 non-covalent complexes with the catalytic zinc cofactor of target MMPs, TIMP-1 controls ECM turnover, tissue remodeling, and wound healing. Beyond its classical protease-inhibitory function, TIMP-1 acts as a multifunctional cytokine and growth factor, engaging cell-surface receptors such as CD63, integrin β1, and CD74 to trigger intracellular signaling pathways (e.g., AKT and MAPK) that promote cell proliferation, survival, and anti-apoptotic responses. Dysregulation of TIMP-1 is strongly implicated in various pathologies, including cancer progression, metastasis, tissue fibrosis, and cardiovascular diseases. Consequently, TIMP-1 is a valuable prognostic biomarker (such as in the Enhanced Liver Fibrosis score) and an attractive therapeutic target. Current drug development strategies focus on downregulating TIMP-1 expression in fibrotic conditions, neutralizing its signaling in oncology, or engineering selective TIMP-1 variants to target specific MMPs while avoiding the musculoskeletal toxicities historically associated with broad-spectrum metalloproteinase inhibitors.

Other names
TIMP1Metalloproteinase inhibitor 1Erythroid-potentiating activityEPAFibroblast collagenase inhibitorCollagenase inhibitorCLGIHCI
02

Mechanism of action

Modulation of TIMP-1 expression (such as downregulation by tipelukast), neutralization of TIMP-1 signaling using monoclonal antibodies, or the use of engineered TIMP-1 variants as selective inhibitors of specific matrix metalloproteinases.

03

Biological functions

Inhibition of matrix metalloproteinasesRegulation of extracellular matrix turnoverPromotion of cell proliferationAnti-apoptotic signalingRegulation of inflammationWound healing
04

Disease associations

CancerFibrosisCardiovascular diseaseInflammationNeurodegenerative diseaseAcute kidney injury
05

Safety considerations

Musculoskeletal toxicityUnintended promotion of tissue scarring and fibrosisImpaired wound healingDisruption of tissue remodeling homeostasisPotential promotion of tumor growth or metastasis due to pleiotropic signaling
06

Interacting drugs

Tipelukast (MN-001)

4 more in the full profile.

07

Biomarkers

Elevated plasma TIMP-1 levelsSerum TIMP-1 levelsUrine TIMP-1 levelsTIMP-1/MMP-9 ratioEnhanced Liver Fibrosis (ELF) score

Beyond the preview

Go deeper on Tissue inhibitor of metalloproteinases-1 (TIMP-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tissue inhibitor of metalloproteinases-1 (TIMP-1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call